Therapeutic Efficacy of Dual-Targeting Nanoparticles with Low Immunogenicity in the Treatment of Rheumatoid Arthritis
Journal of Functional Biomaterials · 06.05.2026 · 17 (5) · 228
DOI: 10.3390/jfb17050228 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Functional Biomaterials, online erschienen am 06.05.2026. Verfasst von Renjie Miao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Frontiers Science Center for Materiobiology and Dynamic Chemistry, East China University of Science and Technology, Shanghai 200237, China. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Plan Project of China, National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Rheumatoid arthritis (RA) treatment is severely hindered by the systemic toxicity and limited joint accumulation of conventional therapeutics. To overcome these critical clinical challenges, we engineered a biomimetic dual-targeted nanoplatform (MTX@HSA@M@HA NPs) to precisely deliver methotrexate (MTX) to inflamed synovia. The rationally designed system encapsulates MTX within human serum albumin (HSA) nanoparticles, which are subsequently cloaked in red blood cell membranes (RBCMs) for robust immune evasion and prolonged systemic circulation. To achieve active targeting, the nanoparticle surface was functionalized with hyaluronic acid (HA) to selectively bind CD44 receptors, which are heavily overexpressed on RA-driving macrophages and fibroblast-like synoviocytes (FLSs). In vitro evaluations demonstrated significantly enhanced cellular internalization by activating RAW264.7 macrophages and FLS, resulting in the potent suppression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) with minimal baseline cytotoxicity. Furthermore, comprehensive in vivo studies using a collagen-induced arthritis (CIA) murine model confirmed that MTX@HSA@M@HA NPs significantly ameliorated joint inflammation, attenuated paw swelling, and rapidly improved functional outcomes compared to free MTX. By synergizing RBCM camouflage with HA-directed active targeting, this nanoplatform maximizes localized therapeutic efficacy while minimizing systemic toxicity, thereby presenting a highly promising and translatable strategy for targeted RA treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Frontiers Science Center for Materiobiology and Dynamic Chemistry, East China University of Science and Technology, Shanghai 200237, China.
- School of Materials Science and Engineering, East China University of Science and Technology, Shanghai 200237, China.
- Engineering Research Center for Biomedical Materials of Ministry of Education, East China University of Science and Technology, Shanghai 200237, China.
ORCID-Profile: Hongyan He
Förderung
- National Key R&D Plan Project of China
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Miao, R., Wang, H., Jin, Y., Liu, C., & He, H. (2026). Therapeutic Efficacy of Dual-Targeting Nanoparticles with Low Immunogenicity in the Treatment of Rheumatoid Arthritis. Journal of Functional Biomaterials, 17(5), 228. https://doi.org/10.3390/jfb17050228
Vancouver
Miao R, Wang H, Jin Y, Liu C, He H. Therapeutic Efficacy of Dual-Targeting Nanoparticles with Low Immunogenicity in the Treatment of Rheumatoid Arthritis. Journal of Functional Biomaterials. 2026;17(5):228. doi:10.3390/jfb17050228
BibTeX
@article{Miao2026,
author = {Miao, Renjie and Wang, Haoyu and Jin, Yitian and Liu, Changsheng and He, Hongyan},
title = {Therapeutic Efficacy of Dual-Targeting Nanoparticles with Low Immunogenicity in the Treatment of Rheumatoid Arthritis},
journal = {Journal of Functional Biomaterials},
year = {2026},
volume = {17},
number = {5},
pages = {228},
doi = {10.3390/jfb17050228}
}
EUVIMED